PNC Financial Services Group
VRDN icon

PNC Financial Services Group’s Viridian Therapeutics VRDN Stock Holding History

PNC Financial Services Group’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.08K Buy
222
+15
+7% +$242 ﹤0.01% 4463
2026
Q1 		$4.05K Buy
207
+74
+56% +$2.2K ﹤0.01% 4357
2025
Q4 		$4.14K Sell
133
-64
-32% -$1.75K ﹤0.01% 4304
2025
Q3 		$4.25K Buy
197
+101
+105% +$1.82K ﹤0.01% 4272
2025
Q2 		$1.34K Sell
96
-766
-89% -$10.4K ﹤0.01% 4513
2025
Q1 		$11.6K Buy
862
+794
+1,168% +$13.5K ﹤0.01% 3771
2024
Q4 		$1.3K Sell
68
-7
-9% -$152 ﹤0.01% 4383
2024
Q3 		$1.71K Buy
75
+42
+127% +$687 ﹤0.01% 4322
2024
Q2 		$429 Buy
33
+13
+65% +$180 ﹤0.01% 4553
2024
Q1 		$350 Sell
20
-40
-67% -$775 ﹤0.01% 4535
2023
Q4 		$1.31K Buy
+60
New +$947 ﹤0.01% 4267

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

PNC Financial Services Group's VRDN Position: Q2 2026 in Review

PNC Financial Services Group increased its Viridian Therapeutics (VRDN) stake by 7.2% in Q2 2026, buying an estimated $242 and bringing the position to 222 shares worth $4.08K. The position accounts for ﹤0.01% of the portfolio, ranked #4463.

PNC Financial Services Group first reported a position in VRDN in Q4 2023 and has held it in 11 quarters since. The position peaked at $11.6K in Q1 2025. 214 funds tracked by Wall St. Rank hold VRDN as of Q2 2026.

  • PNC Financial Services Group held 222 shares of Viridian Therapeutics worth $4.08K as of Q2 2026.
  • PNC Financial Services Group bought 15 Viridian Therapeutics shares in Q2 2026, an estimated $242.
  • Viridian Therapeutics made up ﹤0.01% of PNC Financial Services Group's portfolio in Q2 2026, its #4463 holding.
  • PNC Financial Services Group first reported a position in Viridian Therapeutics in Q4 2023 and has held it in 11 quarters since.
  • PNC Financial Services Group's Viridian Therapeutics position peaked at $11.6K in Q1 2025.
  • 214 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q2 2026.

Based on PNC Financial Services Group's 13F filing for Q2 2026, filed 7 Aug 2026.